Suviray 70mg Injection

Suviray 70 mg Injection contains erenumab, a monoclonal antibody indicated for preventive treatment of migraine in adults. Migraine is a neurological disorder characterised by recurring intense headaches, often accompanied by nausea, photosensitivity, and visual disturbances. For patients with inadequate response to other preventive medications, Suviray offers an alternative approach. The recommended dosage of erenumab should be administered under medical supervision to optimise safety and efficacy in migraine prevention. Patients should understand the use of this medicine in migraine management, potential side effects including fatigue and constipation, and relevant contraindications. This medicine is not recommended in children and adolescents below 18 years of age; elderly patients may require careful monitoring. Consideration of use during pregnancy is important, as administration should occur only on physician recommendation. Appropriate storage conditions and awareness of shelf life are necessary to maintain medicinal integrity. When evaluating erenumab against other monoclonal antibodies such as those in the Aimovig or galcanezumab categories, the choice depends on individual patient response and clinical recommendation. Duration of action may vary depending on individual metabolism and treatment schedules. Review of product information, manufacturer details, available alternatives, and therapeutic benefits should be considered prior to commencing treatment.

Prevention of migraine in adults

Suviray 70 mg Injection works by targeting and inhibiting the calcitonin gene-related peptide (CGRP) receptor. This affects the signaling pathway responsible for sending pain signals and dilation of blood vessels, both of which contribute to the development of migraines. This blockade seeks to minimize the frequency and intensity of migraine attacks, providing a preventive approach to migraine management in adults.

The medicine will be prescribed to you by a healthcare professional in a hospital setting. Suviray 70 mg Injection is administered as a subcutaneous injection. It is injected under the skin, typically in the abdomen or thigh area, once a month. This route of administration allows the medication to be absorbed into the bloodstream and exert its preventive effects on migraines over time. It's important to follow the proper injection technique and guidelines your healthcare provider provides to ensure the medication is administered correctly and safely.

Suviray injection side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Suviray injection side effects are Common: Constipation Itching Vomiting Fatigue Nausea Muscle spasms Injection site reactions Serious: Serious allergic reactions Chronic constipation